MedTrace Logo

Comparison of Repaglinide and Metformin Administered Alone or in Combination in Type 2 Diabetes

NCT01720290 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2017-02-20

No results posted yet for this study

Summary

This trial is conducted in Asia. The aim of this trial is to compare repaglinide and metformin administered alone or in combination in subjects with type 2 diabetes.

Conditions

Interventions

DRUG

repaglinide

Dose individually adjusted

DRUG

metformin

Dose individually adjusted

DRUG

metformin

Dose at 1000 mg/day

Sponsors & Collaborators

Principal Investigators

  • Global Clinical Registry (GCR, 1452) · Novo Nordisk A/S

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2002-07-25
Primary Completion
2003-02-25
Completion
2003-02-25

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01720290 on ClinicalTrials.gov